Crewe Advisors’s 10x Genomics TXG Stock Holding History

Crewe Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-80	Closed	-$2K	–	1275
2022 Q3	$2K	Buy	80 +25	+45%	+$952	﹤0.01%	1087
2022 Q2	$2K	Buy	+55	New	+$2.85K	﹤0.01%	1020

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Crewe Advisors's TXG Position: Q4 2022 in Review

Crewe Advisors sold out of 10x Genomics (TXG) in Q4 2022, closing a stake of 80 shares — an estimated $2K sold.

Crewe Advisors first reported a position in TXG in Q2 2022 and held it in 2 quarters. The position peaked at $2K in Q3 2022. 268 funds tracked by Wall St. Rank hold TXG as of Q4 2022.

Crewe Advisors reported no remaining 10x Genomics position as of Q4 2022 after selling out during the quarter.
Crewe Advisors sold 80 10x Genomics shares in Q4 2022, an estimated $2K.
Crewe Advisors first reported a position in 10x Genomics in Q2 2022 and held it in 2 quarters.
Crewe Advisors's 10x Genomics position peaked at $2K in Q3 2022.
268 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.